These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 27519911)

  • 21. High incidence of aseptic hip necrosis in Hodgkin lymphoma patients treated with escalated BEACOPP receiving methylprednisolone.
    Basic-Kinda S; Karlak I; Durakovic N; Lubina ZI; Livaja Radman I; Dotlic S; Peric Z; Hude I; Aurer I
    Intern Med J; 2018 May; 48(5):523-529. PubMed ID: 29068514
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bleomycin-Induced Flagellate Dermatitis.
    Turan Erkek E; Karaali CN; Yılmaz G; Gültürk E
    Turk J Haematol; 2019 May; 36(2):138-140. PubMed ID: 30600679
    [No Abstract]   [Full Text] [Related]  

  • 23. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.
    Viviani S; Zinzani PL; Rambaldi A; Brusamolino E; Levis A; Bonfante V; Vitolo U; Pulsoni A; Liberati AM; Specchia G; Valagussa P; Rossi A; Zaja F; Pogliani EM; Pregno P; Gotti M; Gallamini A; Rota Scalabrini D; Bonadonna G; Gianni AM; ; ;
    N Engl J Med; 2011 Jul; 365(3):203-12. PubMed ID: 21774708
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group.
    Diehl V; Franklin J; Hasenclever D; Tesch H; Pfreundschuh M; Lathan B; Paulus U; Sieber M; Rueffer JU; Sextro M; Engert A; Wolf J; Hermann R; Holmer L; Stappert-Jahn U; Winnerlein-Trump E; Wulf G; Krause S; Glunz A; von Kalle K; Bischoff H; Haedicke C; Duehmke E; Georgii A; Loeffler M
    J Clin Oncol; 1998 Dec; 16(12):3810-21. PubMed ID: 9850026
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial.
    Engert A; Josting A; Haverkamp H; Villalobos M; Lohri A; Sökler M; Zijlstra J; Sturm I; Topp MS; Rank A; Zenz T; Vogelhuber M; Nogova L; Borchmann P; Fuchs M; Flechtner HH; Diehl V
    J Clin Oncol; 2010 May; 28(13):2239-45. PubMed ID: 20368566
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study.
    Engert A; Diehl V; Franklin J; Lohri A; Dörken B; Ludwig WD; Koch P; Hänel M; Pfreundschuh M; Wilhelm M; Trümper L; Aulitzky WE; Bentz M; Rummel M; Sezer O; Müller-Hermelink HK; Hasenclever D; Löffler M
    J Clin Oncol; 2009 Sep; 27(27):4548-54. PubMed ID: 19704068
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease.
    Diehl V; Franklin J; Pfreundschuh M; Lathan B; Paulus U; Hasenclever D; Tesch H; Herrmann R; Dörken B; Müller-Hermelink HK; Dühmke E; Loeffler M;
    N Engl J Med; 2003 Jun; 348(24):2386-95. PubMed ID: 12802024
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials.
    Sieniawski M; Reineke T; Josting A; Nogova L; Behringer K; Halbsguth T; Fuchs M; Diehl V; Engert A
    Ann Oncol; 2008 Oct; 19(10):1795-801. PubMed ID: 18544558
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ABVD and BEACOPP regimens' effects on fertility in young males with Hodgkin lymphoma.
    Amin MSA; Brunckhorst O; Scott C; Wrench D; Gleeson M; Kazmi M; Ahmed K
    Clin Transl Oncol; 2021 Jun; 23(6):1067-1077. PubMed ID: 32944834
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ten years' experience with four cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, procarbazine (BEACOPP)-escalated followed by four cycles of baseline-dose BEACOPP in patients with advanced stage Hodgkin lymphoma: a single-center, retrospective study.
    Belada D; Štěpánková P; Sýkorová A; Žák P; Smolej L
    Leuk Lymphoma; 2015 Jul; 56(7):2013-8. PubMed ID: 25330440
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of the BEACOPP regimen in refractory and relapsed Hodgkin lymphoma.
    Cavalieri E; Matturro A; Annechini G; De Angelis F; Frattarelli N; Gentilini F; Grapulin L; Sacco M; Torelli F; Vignetti M; Mandelli F; Foà R; Pulsoni A
    Leuk Lymphoma; 2009 Nov; 50(11):1803-8. PubMed ID: 19860621
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is escalated BEACOPP a standard therapy for advanced Hodgkin's disease?
    Carde P; Cavalli F; Diehl V; Franklin J
    Hematol J; 2000; 1(4):282-90. PubMed ID: 11920203
    [No Abstract]   [Full Text] [Related]  

  • 33. Nail dystrophy due to dose-intensive chemotherapy.
    Weihrauch MR; von Bergwelt-Baildon MS
    Int J Hematol; 2009 Jul; 90(1):6-7. PubMed ID: 19543953
    [No Abstract]   [Full Text] [Related]  

  • 34. Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial.
    Gallamini A; Tarella C; Viviani S; Rossi A; Patti C; Mulé A; Picardi M; Romano A; Cantonetti M; La Nasa G; Trentin L; Bolis S; Rapezzi D; Battistini R; Gottardi D; Gavarotti P; Corradini P; Cimminiello M; Schiavotto C; Parvis G; Zanotti R; Gini G; Ferreri AJM; Viero P; Miglino M; Billio A; Avigdor A; Biggi A; Fallanca F; Ficola U; Gregianin M; Chiaravalloti A; Prosperini G; Bergesio F; Chauvie S; Pavoni C; Gianni AM; Rambaldi A
    J Clin Oncol; 2018 Feb; 36(5):454-462. PubMed ID: 29360414
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fertility in young patients following treatment for Hodgkin's lymphoma: a single center survey.
    Boltežar L; Pintarić K; Jezeršek Novaković B
    J Assist Reprod Genet; 2016 Mar; 33(3):325-333. PubMed ID: 26678493
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Treating Hodgkin's disease: for whom the more means better?].
    Illés A
    Magy Onkol; 2004; 48(2):157-61. PubMed ID: 15351812
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BEACOPP: an intensified chemotherapy regimen in advanced Hodgkin's disease. The German Hodgkin's Lymphoma Study Group.
    Diehl V; Sieber M; Rüffer U; Lathan B; Hasenclever D; Pfreundschuh M; Loeffler M; Lieberz D; Koch P; Adler M; Tesch H
    Ann Oncol; 1997 Feb; 8(2):143-8. PubMed ID: 9093722
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment-related mortality in patients with advanced-stage hodgkin lymphoma: an analysis of the german hodgkin study group.
    Wongso D; Fuchs M; Plütschow A; Klimm B; Sasse S; Hertenstein B; Maschmeyer G; Vieler T; Dührsen U; Lindemann W; Aulitzky W; Diehl V; Borchmann P; Engert A
    J Clin Oncol; 2013 Aug; 31(22):2819-24. PubMed ID: 23796987
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PET-positive bone lesion due to Langerhans cell histiocytosis after BEACOPP therapy for Hodgkin lymphoma: how anamnesis, histopathological accuracy, and molecular analysis could resolve a clinical dilemma.
    Haefliger S; Bihl M; Krasniqi F; Tzankov A
    Ann Hematol; 2018 Feb; 97(2):355-357. PubMed ID: 28975389
    [No Abstract]   [Full Text] [Related]  

  • 40. Whole-body MRI reveals high incidence of osteonecrosis in children treated for Hodgkin lymphoma.
    Littooij AS; Kwee TC; Enríquez G; Verbeke JI; Granata C; Beishuizen A; de Lange C; Zennaro F; Bruin MC; Nievelstein RA
    Br J Haematol; 2017 Feb; 176(4):637-642. PubMed ID: 27891588
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.